[1]Khan,SaeedR.;Mhaka,Annastasiah;Pili,Roberto;Isaacs,JohnT.[BioorganicandMedicinalChemistryLetters,2001,vol.11,#4,p.451-452]
[1]Jönsson,Stig;Andersson,Gunnar;Fex,Tomas;Fristedt,Tomas;Hedlund,Gunnar;Jansson,Karl;Abramo,Lisbeth;Fritzson,Ingela;Pekarski,Olga;Runström,Anna;Sandin,Helena;Thuvesson,Ingela;Björk,Anders[JournalofMedicinalChemistry,2004,vol.47,#8,p.2075-2088]
[2]Shi,Jiandong;Xiao,Zili;Ihnat,MichaelA.;Kamat,Chandrashekhar;Pandit,Bulbul;Hu,Zhigen;Li,Pui-Kai[BioorganicandMedicinalChemistryLetters,2003,vol.13,#6,p.1187-1189]
[1]Jönsson,Stig;Andersson,Gunnar;Fex,Tomas;Fristedt,Tomas;Hedlund,Gunnar;Jansson,Karl;Abramo,Lisbeth;Fritzson,Ingela;Pekarski,Olga;Runström,Anna;Sandin,Helena;Thuvesson,Ingela;Björk,Anders[JournalofMedicinalChemistry,2004,vol.47,#8,p.2075-2088]
[1]Jönsson,Stig;Andersson,Gunnar;Fex,Tomas;Fristedt,Tomas;Hedlund,Gunnar;Jansson,Karl;Abramo,Lisbeth;Fritzson,Ingela;Pekarski,Olga;Runström,Anna;Sandin,Helena;Thuvesson,Ingela;Björk,Anders[JournalofMedicinalChemistry,2004,vol.47,#8,p.2075-2088]
[2]Shi,Jiandong;Xiao,Zili;Ihnat,MichaelA.;Kamat,Chandrashekhar;Pandit,Bulbul;Hu,Zhigen;Li,Pui-Kai[BioorganicandMedicinalChemistryLetters,2003,vol.13,#6,p.1187-1189]
[3]Sjoevall,Sven;Hansen,Lars;Granquist,Bo[OrganicProcessResearchandDevelopment,2004,vol.8,#5,p.802-807]
[1]Jönsson,Stig;Andersson,Gunnar;Fex,Tomas;Fristedt,Tomas;Hedlund,Gunnar;Jansson,Karl;Abramo,Lisbeth;Fritzson,Ingela;Pekarski,Olga;Runström,Anna;Sandin,Helena;Thuvesson,Ingela;Björk,Anders[JournalofMedicinalChemistry,2004,vol.47,#8,p.2075-2088]
Title: H1521, a novel derivative of 4-hydroxyquinoline-3-carboxamide, suppresses the development of lupus in mice by inducing Th1 cytokine profile in T cells.
Journal: International immunopharmacology 20110401
Title: The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.
Journal: Expert opinion on investigational drugs 20101001
Title: Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine production.
Journal: Life sciences 20071027
Title: Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
Journal: The Prostate 20061201
Title: Design, synthesis, and biological evaluation of novel 4-hydro-quinoline-3-carboxamide derivatives as an immunomodulator.
Journal: Bioorganic & medicinal chemistry letters 20050615
Title: Effect of Linomide on adhesion molecules, TNF-alpha, nitrogen oxide, and cell adhesion.
Journal: International immunopharmacology 20050201
Title: Interleukin-10 mediates the protective effect of Linomide by reducing CXC chemokine production in endotoxin-induced liver injury.
Journal: British journal of pharmacology 20041201
Title: Immunomodulation by roquinimex decreases the expression of IL-23 (p19) mRNA in the brains of herpes simplex virus type 1 infected BALB/c mice.
Journal: Clinical and experimental immunology 20040801
Title: Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
Journal: Journal of medicinal chemistry 20040408
Title: Structure-activity relationships studies of the anti-angiogenic activities of linomide.
Journal: Bioorganic & medicinal chemistry letters 20030324
Title: Roquinimex inhibits dextran sodium sulfate-induced murine colitis.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20030201
Title: Semliki Forest virus infection is enhanced in Th1-prone SJL mice but not in Th2-prone BALB/c mice during Linomide-induced immunomodulation.
Journal: Journal of neuroimmunology 20021101
Title: Quinoline-3-carbothioamides and related compounds as novel immunomodulating agents.
Journal: Bioorganic & medicinal chemistry letters 20020902
Title: The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
Journal: Journal of neuroimmunology 20020901
Title: Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue.
Journal: Neuropharmacology 20020401
Title: Protective effect of Linomide on TNF-alpha-induced hepatic injury.
Journal: Journal of hepatology 20020201
Title: Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system.
Journal: International immunopharmacology 20010601
Title: The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus.
Journal: International immunopharmacology 20010601
Title: Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis.
Journal: Archives of neurology 20010101
Title: Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20000901
Title: Roquinimex, From Wikipedia
Title: Liu Q, et al. Roquinimex inhibits dextran sodium sulfate-induced murine colitis. Inflamm Res. 2003 Feb;52(2):64-8.
Title: Tian WZ, et al. Linomide (roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis. Acta Neurol Scand. 1998 Aug;98(2):94-101.